Daniel P. Petrylak, MD, Professor of Medicine (Medical Oncology) and of Urology, Professor and Co-Director, Signal Transduction Research Program, Yale Cancer Center, discusses results from the phase II STRIDE study.
The randomized STRIDE study evaluated concurrent versus sequential enzalutamide in combination with sipuleucel-T for the treatment of patients with metastatic castration-resistant prostate cancer.
There was no difference seen in immune parameters when comparing early and delayed enzalutamide. Further, Petrylak said, the prime-boost effect was similar in the two arms.
Anecdotally, Petrylak said, no additive or synergistic toxicities were observed. Full toxicity data will be reported later.
<<< View more from the 2014 ESMO Congress